A theoretical examination of the relative importance of evolution management and drug development for managing resistance

Diagnostics: Detection drives defence

(2014) Rebecca Kanthor   NATURE

Public health: The politics of antibiotics

(2014) Megan Cully   NATURE

Drug development: Time for teamwork

(2014) Mike May   NATURE

Antibiotic resistance: An infectious arms race

(2014) Karyn Hede   NATURE

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

(2013) Stephen D Lawn et al.   LANCET INFECTIOUS DISEASES

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

(2012) Daniel E. Goldberg et al.   CELL

The numbers game

(2012) Priya Shetty   NATURE

National and international policies to mitigate disease threats

(2012) C. Dye   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

“One-Size-Fits-All”? Optimizing Treatment Duration for Bacterial Infections

(2012) Patricia Geli et al.   PLoS One

Combination therapies for combating antimicrobial resistance

(2011) Michael A Fischbach   CURRENT OPINION IN MICROBIOLOGY

Research Spotlight: The TB Alliance: overcoming challenges to chart the future course of TB drug development

(2011) Ann Ginsberg   Future Medicinal Chemistry

Population biological principles of drug-resistance evolution in infectious diseases

(2011) Pia Abel zur Wiesch et al.   LANCET INFECTIOUS DISEASES

The challenge of new drug discovery for tuberculosis

(2011) Anil Koul et al.   NATURE

The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy

(2011) A. F. Read et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

On Being the Right Size: The Impact of Population Size and Stochastic Effects on the Evolution of Drug Resistance in Hospitals and the Community

(2011) Roger D. Kouyos et al.   PLoS Pathogens

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

(2010) Neel R Gandhi et al.   LANCET

Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty

(2010) David L Smith et al.   MALARIA JOURNAL

How to improve R&D productivity: the pharmaceutical industry's grand challenge

(2010) Steven M. Paul et al.   NATURE REVIEWS DRUG DISCOVERY

Has the era of untreatable infections arrived?

(2009) D. M. Livermore   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

(2009) Patrice Nordmann et al.   LANCET INFECTIOUS DISEASES

Lessons from 60 years of pharmaceutical innovation

(2009) Bernard Munos   NATURE REVIEWS DRUG DISCOVERY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial stewardship: concepts and strategies in the 21st century

(2008) Robert C. Owens   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimalarial drug use in general populations of tropical Africa

(2008) Florence Gardella et al.   MALARIA JOURNAL

Benefits of using multiple first-line therapies against malaria

(2008) M. F. Boni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America

(2007) B. Spellberg et al.   CLINICAL INFECTIOUS DISEASES